Roth, Bryan L.

Inhibition of mediodorsal thalamus disrupts thalamofrontal connectivity and cognition

Parnaudeau, S., O’Neill, P.-K., Bolkan, S. S., Ward, R. D., Abbas, A. I., Roth, B. L., Balsam, P. D., Gordon, J. A., & Kellendonk, C. (2013) · Neuron

Schizophrenia research and treatmentNeural dynamics and brain function

Cited by 387

Unexplored therapeutic opportunities in the human genome

Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery

Computational Drug Discovery MethodsBioinformatics and Genomic Networks

Cited by 378

Remote Control of Neuronal Signaling

Rogan, S. C., & Roth, B. L. (2011) · Pharmacological Reviews

Photoreceptor and optogenetics researchNeuroscience and Neuropharmacology Research

Cited by 339

Comprehensive characterization of the Published Kinase Inhibitor Set

Elkins, J. M., Fedele, V., Szklarz, M., Abdul Azeez, K. R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., Huang, X.-P., Roth, B. L., et al. (2016) · Nature Biotechnology

Computational Drug Discovery MethodsProtein Kinase Regulation and GTPase Signaling

Cited by 323

In silico design of novel probes for the atypical opioid receptor MRGPRX2

Lansu, K., Karpiak, J., Liu, J., Huang, X.-P., McCorvy, J. D., Kroeze, W. K., Che, T., Nagase, H., Carroll, F. I., Jin, J., et al. (2017) · Nature Chemical Biology

Computational Drug Discovery MethodsReceptor Mechanisms and Signaling

Cited by 293

Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65

Huang, X.-P., Karpiak, J., Kroeze, W. K., Zhu, H., Chen, X., Moy, S. S., Saddoris, K. A., Nikolova, V. D., Farrell, M. S., Wang, S., et al. (2015) · Nature

Receptor Mechanisms and SignalingComputational Drug Discovery Methods

Cited by 284

Community guidelines for GPCR ligand bias: IUPHAR review 32

Kolb, P., Kenakin, T., Alexander, S. P. H., Bermudez, M., Bohn, L. M., Breinholt, C. S., Bouvier, M., Hill, S. J., Kostenis, E., Martemyanov, K. A., et al. (2022) · British Journal of Pharmacology

Receptor Mechanisms and SignalingNeuroscience and Neuropharmacology Research

Cited by 232

Rapid modulation of spine morphology by the 5-HT 2A serotonin receptor through kalirin-7 signaling

Jones, K. A., Srivastava, D. P., Allen, J. A., Strachan, R. T., Roth, B. L., & Penzes, P. (2009) · Proceedings of the National Academy of Sciences

Neuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

Cited by 226

Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors

Allen, J. A., & Roth, B. L. (2011) · Annual Review of Pharmacology and Toxicology

Receptor Mechanisms and SignalingComputational Drug Discovery Methods

Cited by 216

Structures of the σ2 receptor enable docking for bioactive ligand discovery

Alon, A., Lyu, J., Braz, J. M., Tummino, T. A., Craik, V., O’Meara, M. J., Webb, C. M., Radchenko, D. S., Moroz, Y. S., Huang, X.-P., et al. (2021) · Nature

Pharmacological Receptor Mechanisms and EffectsReceptor Mechanisms and Signaling

Cited by 211

Modulation of the autonomic nervous system and behaviour by acute glial cell G q protein‐coupled receptor activation in vivo

Agulhon, C., Boyt, K. M., Xie, A. X., Friocourt, F., Roth, B. L., & McCarthy, K. D. (2013) · The Journal of Physiology

Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and Signaling

Cited by 147

Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats

Nemeth, C. L., Paine, T. A., Rittiner, J. E., Béguin, C., Carroll, F. I., Roth, B. L., Cohen, B. M., & Carlezon, W. A. (2010) · Psychopharmacology

Neurotransmitter Receptor Influence on BehaviorPsychedelics and Drug Studies

Cited by 104

Discovery of new GPCR ligands to illuminate new biology

Roth, B. L., Irwin, J. J., & Shoichet, B. K. (2017) · Nature Chemical Biology

Receptor Mechanisms and SignalingComputational Drug Discovery Methods

Cited by 94

Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace

Baumann, M. H., Majumdar, S., Le Rouzic, V., Hunkele, A., Uprety, R., Huang, X. P., Xu, J., Roth, B. L., Pan, Y.-X., & Pasternak, G. W. (2018) · Neuropharmacology

Forensic Toxicology and Drug AnalysisOpioid Use Disorder Treatment

Cited by 92

Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily

Roth, B. L., & Kroeze, W. K. (2015) · Journal of Biological Chemistry

Receptor Mechanisms and SignalingComputational Drug Discovery Methods

Cited by 88

Life Beyond Kinases: Structure-Based Discovery of Sorafenib as Nanomolar Antagonist of 5-HT Receptors

Lin, X., Huang, X.-P., Chen, G., Whaley, R., Peng, S., Wang, Y., Zhang, G., Wang, S. X., Wang, S., Roth, B. L., et al. (2012) · Journal of Medicinal Chemistry

Computational Drug Discovery MethodsReceptor Mechanisms and Signaling

Cited by 73

The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand

Chan, J. D., Cupit, P. M., Gunaratne, G. S., McCorvy, J. D., Yang, Y., Stoltz, K., Webb, T. R., Dosa, P. I., Roth, B. L., Abagyan, R., et al. (2017) · Nature Communications

Parasites and Host InteractionsReceptor Mechanisms and Signaling

Cited by 69

Hallucinogen actions on human brain revealed

Lee, H.-M., & Roth, B. L. (2012) · Proceedings of the National Academy of Sciences

Psychedelics and Drug StudiesHallucinations in medical conditions

Cited by 46

Application of Quantitative Structure–Activity Relationship Models of 5-HT1A Receptor Binding to Virtual Screening Identifies Novel and Potent 5-HT1A Ligands

Luo, M., Wang, X. S., Roth, B. L., Golbraikh, A., & Tropsha, A. (2014) · Journal of Chemical Information and Modeling

Computational Drug Discovery MethodsReceptor Mechanisms and Signaling

Cited by 37

Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo

Allen, J. A., Yadav, P. N., Setola, V, Farrell, M., & Roth, B. L. (2011) · Translational Psychiatry

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 37

HTS and Rational Drug Design to Generate a Class of 5‐HT2C‐Selective Ligands for Possible Use in Schizophrenia.

Kozikowski, A. P., Cho, S. J., Jensen, N. H., Allen, J. A., Svennebring, A. M., & Roth, B. L. (2010) · ChemMedChem

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 28

Advancing drug discovery for schizophrenia

Marder, S. R., Roth, B., Sullivan, P. F., Scolnick, E. M., Nestler, E. J., Geyer, M. A., Welnberger, D. R., Karayiorgou, M., Guidotti, A., Gingrich, J., et al. (2011) · Annals of the New York Academy of Sciences

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 25